Please assess the completion status of the following clinical trial:

Trial Title: Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject suffering from generalized prurigo nodularis~* Have demonstrated pruritus intensity during screening~* Male or female who are at least 18 years old at the time of consent~Exclusion Criteria:~* Subject has chronic pruritus resulting from other conditions~* Subject has a history of substance abuse within the past year~* Subject has a known drug allergy to opioids~* Subject is a pregnant or lactating female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- nalbuphine HCl ER 90mg (Type: EXPERIMENTAL): nalbuphine HCl ER tablets 90 mg BID
- nalbuphine HCl ER 180 mg (Type: EXPERIMENTAL): nalbuphine HCl ER tablets 180 mg BID
- Sugar pill (Type: PLACEBO_COMPARATOR): Placebo tablets BID

Based on this trial design, predict the completion outcome and termination type (if applicable).